# PERYTON (NCT04642027)

> PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: prostate cancer with biochemical failure after radical prostatectomy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04642027
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University Medical Center Groningen
- Conditions: Prostate Cancer; Cancer Recurrence
- Interventions: Conventional sEBRT; Hypofractionated sEBRT
- Enrollment: 538
- Primary outcome: 5-year progression-free survival

## Indexed commentary on PERYTON so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=peryton-nct04642027